PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.95%
Positive revenue growth while XRF.AX is negative. John Neff might see a notable competitive edge here.
-6.92%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-42.00%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-42.00%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
94.54%
Net income growth above 1.5x XRF.AX's 13.78%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
50.00%
EPS growth above 1.5x XRF.AX's 12.54%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
100.00%
Diluted EPS growth above 1.5x XRF.AX's 12.54%. David Dodd would see if there's a robust moat protecting these shareholder gains.
44.17%
Share count expansion well above XRF.AX's 1.21%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
37.23%
Diluted share count expanding well above XRF.AX's 1.24%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
267.68%
Positive OCF growth while XRF.AX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
290.19%
Positive FCF growth while XRF.AX is negative. John Neff would see a strong competitive edge in net cash generation.
-77.63%
Negative 10Y revenue/share CAGR while XRF.AX stands at 151.40%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-47.51%
Negative 5Y CAGR while XRF.AX stands at 74.52%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-8.54%
Negative 3Y CAGR while XRF.AX stands at 49.22%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
156.32%
10Y OCF/share CAGR 1.25-1.5x XRF.AX's 132.15%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
439.03%
Below 50% of XRF.AX's 1139.05%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
214.30%
3Y OCF/share CAGR 1.25-1.5x XRF.AX's 144.47%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
134.43%
Net income/share CAGR at 50-75% of XRF.AX's 198.79%. Martin Whitman might question if the firm’s product or cost base lags behind.
877.36%
5Y net income/share CAGR above 1.5x XRF.AX's 195.12%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
772.00%
3Y net income/share CAGR above 1.5x XRF.AX's 72.97%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18383.98%
3Y equity/share CAGR above 1.5x XRF.AX's 30.57%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.84%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-13.53%
Inventory is declining while XRF.AX stands at 4.59%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
16.39%
Positive asset growth while XRF.AX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
22.11%
Positive BV/share change while XRF.AX is negative. John Neff sees a clear edge over a competitor losing equity.
48.69%
Debt growth far above XRF.AX's 35.08%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
100.04%
R&D growth of 100.04% while XRF.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-4.79%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.